Disclosures for "Impact of the Oral Orexin Receptor 2 Agonist TAK-994 on Sustained Attention in Patients with Narcolepsy Type 1: Exploratory Results from a Phase 2 Study"
-
Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for idorsia. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avadel.
-
The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TAKEDA. The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOPROJET. The institution of Dr. Plazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. The institution of Dr. Plazzi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for OREXIA. The institution of Dr. Plazzi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for OREXIA/CENTESSA.
-
Dr. Koundourakis has nothing to disclose.
-
Mr. Du has received personal compensation for serving as an employee of Takeda. Mr. Du has stock in Takeda.
-
Dr. Von Hehn has received personal compensation for serving as an employee of Takeda.
-
Mr. Volfson has received personal compensation for serving as an employee of Takeda. Mr. Volfson has stock in Takeda.
-
Dr. Latzman has received personal compensation for serving as an employee of Takeda Pharmaceutical Company Limited. Dr. Latzman has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Personality Assessment. Dr. Latzman has stock in Takeda Pharmaceutical Company Limited.
-
Brian Harel has received personal compensation for serving as an employee of Takeda. An immediate family member of Brian Harel has received personal compensation for serving as an employee of Astra Zeneca. Brian Harel has stock in Takeda, Merck, Day One Biopharmaceuticals. An immediate family member of Brian Harel has stock in Eli Lilly, Pfizer, Astra Zeneca. Brian Harel has stock in Cogstate.